| dc.contributor.author | Yap, TA | |
| dc.contributor.author | Smith, AD | |
| dc.contributor.author | Ferraldeschi, R | |
| dc.contributor.author | Al-Lazikani, B | |
| dc.contributor.author | Workman, P | |
| dc.contributor.author | de Bono, JS | |
| dc.date.accessioned | 2017-11-24T12:31:57Z | |
| dc.date.issued | 2016-10-01 | |
| dc.identifier.citation | Nature reviews. Drug discovery, 2016, 15 (10), pp. 699 - 718 | |
| dc.identifier.issn | 1474-1776 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/950 | |
| dc.identifier.eissn | 1474-1784 | |
| dc.identifier.doi | 10.1038/nrd.2016.120 | |
| dc.description.abstract | Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs. | |
| dc.format | Print-Electronic | |
| dc.format.extent | 699 - 718 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | NATURE PUBLISHING GROUP | |
| dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
| dc.subject | Animals | |
| dc.subject | Humans | |
| dc.subject | Antineoplastic Agents | |
| dc.subject | Male | |
| dc.subject | Drug Discovery | |
| dc.subject | Molecular Targeted Therapy | |
| dc.subject | Translational Medical Research | |
| dc.subject | Genetic Therapy | |
| dc.subject | Prostatic Neoplasms, Castration-Resistant | |
| dc.subject | Biomarkers, Tumor | |
| dc.title | Drug discovery in advanced prostate cancer: translating biology into therapy. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2016-07-22 | |
| rioxxterms.versionofrecord | 10.1038/nrd.2016.120 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2016-10 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Nature reviews. Drug discovery | |
| pubs.issue | 10 | |
| pubs.notes | 6 months | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
| pubs.publication-status | Published | |
| pubs.volume | 15 | |
| pubs.embargo.terms | 6 months | |
| icr.researchteam | Computational Biology and Chemogenomics | |
| icr.researchteam | Medicine Drug Development Unit (de Bono) | |
| icr.researchteam | Prostate Cancer Targeted Therapy Group | |
| dc.contributor.icrauthor | Al-Lazikani, Bissan | |
| dc.contributor.icrauthor | Workman, Paul | |
| dc.contributor.icrauthor | De Bono, Johann | |
